India has bolstered its Pharmaceutical Manufacturing Linked Incentive (PLI) scheme to reduce reliance on Chinese imports. With an initial outlay of ₹6,940 crore, the government aims to strengthen the domestic drug manufacturing industry. The PLI schemes, running from 2022-2023 to 2028-29, cover various sectors, including medical devices, pharmaceuticals, and bulk drugs. Under the bulk drugs […]